| Literature DB >> 28321152 |
Rodolfo Pessato Timoteo1, Marcos Vinicius da Silva1, Camila Botelho Miguel1, Djalma Alexandre Alves Silva1, Jonatas Da Silva Catarino1, Virmondes Rodrigues Junior1, Helioswilton Sales-Campos1, Carlo Jose Freire Oliveira1.
Abstract
Pemphigus vulgaris (PV) is an autoimmune disease characterized by the presence of IgG autoantibodies against desmoglein-3. Despite the variety of findings, the chemokine and cytokine profiles that characterize the immune response in the disease are still poorly explored. Thus, 20 PV patients and 20 controls were grouped according to gender, ethnicity, place of residence, and clinical parameters of the disease. Then, the levels of chemokines and of Th1/Th2/Th17/Treg/Th9/Th22-related cytokines were assessed in the serum. PV patients had higher levels of inflammatory Th1/Th17 cytokines (IFN-γ, IL-17, and IL-23), as well as higher levels of CXCL8 and reduced levels of Th1/Th2-related chemokines (IP-10 and CCL11). However, no differences in the levels of IL-2, IL-6, TNF-α, IL-1β, IL-4, IL-9, IL-12, TGF-β, IL-33, MCP-1, RANTES, and MIP-1α were found between PV patients and their control counterparts. Furthermore, PV patients with skin lesions had higher serum levels of IL-6 and CXCL8 when compared to PV patients without lesions. Taken together, our findings describe the role of cytokines and chemokines associated with Th1/Th17 immune response in PV patients. Finally, these data are important for better understanding of the immune aspects that control disease outcome, and they may also provide important information about why patients develop autoantibodies against desmogleins.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28321152 PMCID: PMC5340942 DOI: 10.1155/2017/7151285
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Clinical findings in controls and in patients with Pemphigus vulgaris (PV).
| Controls | PV patients | |
|---|---|---|
| Age (median ± SD) | 35.38 ± 14.24 | 41.47 ± 15.82 |
| Gender | 7 M/13 F | 5 M/15 F |
| Skin color: | ||
| Biracial | 4 | 8 |
| White | 12 | 11 |
| Black | 4 | 2 |
| Living areas: | ||
| Urban area | 11 | 6 |
| Urban and rural areas | 8 | 11 |
| Rural area | 1 | 3 |
SD = standard deviation; M = males; F = females.
Age, cutaneous involvement, and treatment used by Pemphigus vulgaris patients.
| Gender | Age (years) | Cutaneous involvement | Treatment period | Concomitant medications (dosage) | |
|---|---|---|---|---|---|
| (1) | Female | 43 | No lesions | 4 years | Prednisone (5 mg), dapsone (100 mg) |
| (2) | Male | 64 | Mild hyperpigmentation | 9 years | Dapsone (50 mg) |
| (3) | Female | 21 | 99% hyperpigmentation | 3 years | Prednisone (10 mg), dapsone (100 mg), vitamin D |
| (4) | Female | 38 | 99% hyperpigmentation | 3 years | Prednisone (15 mg), dapsone (150 mg), vitamin D |
| (5) | Female | 68 | 37% erythema | 1 year | Prednisone (20 mg) |
| (6) | Female | 53 | 9% hyperpigmentation | 1 year | Predisim (3 mg), azathioprine |
| (7) | Female | 48 | No lesions | 1 year | Prednisone (30 mg), Dapsone (100 mg) |
| (8) | Female | 35 | No lesions | 5 years | Prednisone (20 mg), dapsone (80 mg) |
| (9) | Female | 12 | 99% hyperpigmentation | 4 months | Prednisone (20 mg) |
| (10) | Female | 47 | 90% hyperpigmentation and erythema | 6 years | Prednisone (20 mg) |
| (11) | Male | 16 | 36% hyperpigmentation | 3 years | Prednisone (20 mg) |
| (12) | Male | 26 | Lesions in granulation phase | 2 years | Cyclosporine (250 mg) |
| (13) | Female | 48 | 40% granulomatous lesions | 3 years | Prednisone (20 mg), dapsone (100 mg) |
| (14) | Male | 63 | Oral lesions and bruises on segments | 6 months | Prednisone (60 mg) |
| (15) | Male | 28 | 90% active lesions and erythema | 1 year | Prednisone (60 mg), dapsone (100 mg) |
| (16) | Female | 46 | 99% acute lesions | 3 months | Prednisone (60 mg), dapsone (100 mg) |
| (17) | Female | ni | 99% acute lesions | 11 months | Prednisone (60 mg) |
| (18) | Female | 47 | 99% acute lesions and hyperpigmentation | 2 years | |
| (19) | Female | 50 | 54% hyperpigmentation and erythema | 2 years | Prednisone (50 mg), Dapsone (100 mg), levothyroxine |
| (20) | Female | 35 | 36% granulomatous lesions | Prednisone (40 mg), dapsone (100 mg) |
Figure 1Serum profile of T cell-derived cytokines in Pemphigus vulgaris. Levels of (a) IFN-γ, (b) IL-17, (c) IL-10, and (d) IL-22 in Healthy Donors (⬤) and Pemphigus vulgaris patients (■). Error bars represent median ± SD. p < 0.05; p < 0.01; p < 0.001; p < 0.0001; Mann–Whitney test. (e) Radar plot representation of serum T cell-derived cytokine profile. The lines highlight the fold change in cytokine levels in Pemphigus vulgaris patients (gray line) in relation to Healthy Donors (black line). Data were obtained by calculating the ratio between the median concentration of each cytokine in the Pemphigus vulgaris group and in the healthy group.
Figure 2Serum profile of other proinflammatory cytokines in Pemphigus vulgaris. Levels of (a) IL-2, (b) TNF-α, (c) IL-12, (d) IL-6, (e) IL-23, (f) IL-13, (g) IL-5, (h) IL-15, and (i) IL-33 in Healthy Donors (⬤) and Pemphigus vulgaris patients (■). Error bars represent median ± SD. p < 0.05; p < 0.01; p < 0.0001; Mann–Whitney test. (j) Radar plot representation of serum proinflammatory cytokine profile. The lines highlight the fold change in cytokine levels in Pemphigus vulgaris patients (gray line) in relation to Healthy Donors (black line). Data were obtained by calculating the ratio between the median concentration of each cytokine in the Pemphigus vulgaris group and in the healthy group.
Figure 3Serum profile of chemokines in Pemphigus vulgaris. Levels of (a) CCL-2/MCP-1, (b) CCL5/RANTES, (c) CCL11/Eotaxin, (d) CXCL8/IL-8, and (e) CCL10/IP-10 in Healthy Donors (⬤) and Pemphigus vulgaris patients (■). Error bars represent median ± SD. p < 0.001; p < 0.0001; Mann–Whitney test. (f) Radar plot representation of serum chemokine pattern. The lines highlight the fold change in cytokine levels in Pemphigus vulgaris patients (gray line) in relation to controls (black line). Data were obtained by calculating the ratio between the median concentration of each cytokine in the Pemphigus vulgaris group and in the control group.
Figure 4Skin lesions in Pemphigus vulgaris are associated with higher levels of IL-6 and CXCL8. Levels of (a) IL-2, (b) IL-6, and (c) CXL8 (IL-8) in Pemphigus vulgaris (PV) patients with no skin lesions (⬤) and PV patients with skin lesions (■). (d) Correlation between the frequency of lesions and time of treatment and (e) correlation between the frequency of skin lesions and dosage of glucocorticoids used to treat PV patients. Error bars represent median ± SD. p < 0.05, Mann–Whitney test was used in (a–c). The Spearman correlation test was used to evaluate the strength of association between the variables (d and e).